BioDelivery Sciences International is an American specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions. It was incorporated in 1997 and is headquartered in Raleigh, North Carolina.
The company's stock is not traded due to a acquisition by Collegium Pharmaceutical
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential
BioDelivery Sciences International news
14.02.2022
Collegium Pharmaceutical acquires BioDelivery Sciences for $604 million, or $5.6 per share. The transaction is scheduled to close at the end of Q1 2022.
Source: 
ir.bdsi.com
ir.bdsi.com
03.11.2021
BioDelivery Sciences International's GAAP net income for 9M 2021 was $20.97 million, up 35.2% from $15.515 million in the previous year. Revenue increased 8.1% to $123.549 million from $114.304 million a year earlier.
Source: ir.bdsi.com
ir.bdsi.com
09.09.2021
BioDelivery Sciences International has acquired the US and Canadian rights to ELYXYB from Dr. Reddy's Laboratories. ELYXYB is the only FDA-approved oral solution for the treatment of acute migraine. BioDelivery plans to begin selling ELYXYB in Q1 2022.
Source: ir.bdsi.com
ir.bdsi.com
04.08.2021
BioDelivery Sciences International's net income on GAAP for 6 months of 2021 amounted to $14.301 million, increasing 2.3 times compared to $6.131 million in the previous year. Revenue increased 10.1% to $82.458 million from $74.861 million a year earlier.
Source: ir.bdsi.com
ir.bdsi.com
General information
| Company name | BioDelivery Sciences International |
|---|---|
| Tags | #pharmacy |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals |
| Business address | 4131 ParkLake Avenue Suite 225 Raleigh, NC 27612 United States |
| Mailing address | 4131 ParkLake Avenue Suite 225 Raleigh, NC 27612 United States |
| Website | ir.bdsi.com |
| Information disclosure | www.sec.gov |
English (US) 